Analysis of the Utilization of Lipid-regulating Agents from 74 Hospitals in 6 Areas of China in 2013
10.6039/j.issn.1001-0408.2015.35.05
- VernacularTitle:北京、成都等六地区74家医院2013年调脂药使用分析
- Author:
Xiubo SUN
;
Yatong ZHANG
;
Yichen HE
;
Lei LIU
- Publication Type:Journal Article
- Keywords:
Hyperlipidemia;
Lipid-regulating agents;
Epidemiological investigation;
Beijing;
Chengdu;
Guangzhou;
Hang-zhou;
Shanghai;
Tianjin
- From:
China Pharmacy
2015;26(35):4908-4911
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To provide reference for drug procurement and supply and rational use of lipid-regulating agents. METHODS:The epidemiological investigation was carried out among 159 506 cases from 74 hospitals in Beijing,Chengdu, Guangzhou,Hangzhou,Shanghai and Tianjin in 2013. The utilization of lipid-regulating agents was analyzed statistically in re-spects of purchase value,DDDs,DDC,actual average daily dose and sort ratio. RESULTS:The prevalence rate of hyperlipidemia was relatively high,accounting for 29.56% and showing a tendency of regional distribution and young age in all regions. The pa-tients with hypertension,diabetes and coronary heart disease had a higher incidence to suffer from hyperlipidemia. The use of atorv-astatin was in the first place,but it also had a higher DDC;while rosuvastatin hasd the advantage over aorvastatin in drug market. Simvastatin had a lower DDC and was more suitable for the patients with low income. The doses of lipid-regulating agents in other regions were lower than DDD except for those in Beijing and Tianjin. CONCLUSIONS:Statins dominate the lipid-regulating agents market. But new lipid-regulating agents and drug combination provide a new choice for clinical treatment.
